Repligen (NASDAQ:RGEN) Shares Gap Up to $138.00

Shares of Repligen Co. (NASDAQ:RGEN) gapped up prior to trading on Tuesday . The stock had previously closed at $138.00, but opened at $152.68. Repligen shares last traded at $154.00, with a volume of 380,810 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RGEN. JPMorgan Chase & Co. reduced their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. Guggenheim started coverage on Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. Finally, Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

The stock has a market cap of $8.66 billion, a P/E ratio of 622.18, a P/E/G ratio of 4.71 and a beta of 0.96. The firm has a 50 day moving average of $134.79 and a two-hundred day moving average of $166.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the prior year, the company posted $0.64 earnings per share. The firm’s revenue was down 17.1% compared to the same quarter last year. On average, research analysts predict that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Martin D. Madaus acquired 1,615 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the transaction, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Martin D. Madaus acquired 1,615 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were bought at an average price of $124.94 per share, with a total value of $201,778.10. Following the acquisition, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several large investors have recently modified their holdings of RGEN. YHB Investment Advisors Inc. acquired a new stake in Repligen in the 1st quarter valued at $26,000. Lazard Asset Management LLC lifted its holdings in shares of Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares in the last quarter. Principal Securities Inc. bought a new stake in shares of Repligen in the 4th quarter worth about $48,000. Finally, GAMMA Investing LLC grew its stake in Repligen by 183.4% during the second quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company’s stock worth $60,000 after buying an additional 310 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.